Kornimate/medical-research-clean huggingface dataset:
a pilot study to evaluate the efficacy of adapalene 0.3% for use in the prevention and treatment of senile purpura

Conditions: Senile Purpura

Summary: this is an open label 6 month pilot study for male and female participants over the age of 52 that desire treatment and prevention of senile purpura of the forearms. this study will be evaluating the effects of adapalene 0.3% for the use in the treatment and prevention of senile purpura.

this is a new potential use for the product adapalene 0.3%, which is currently an fda approved topical treatment used for the treatment of acne. senile purpura is a common sign of aging that appears in the form of dark blotches on the skin and is caused by bruising. older adults tend to be more prone to bruising, since as people age, their skin becomes thinner and more fragile.

Eligibility criteria:
inclusion criteria: * male or female over 52 years of age with signs of senile purpura on either the right or left (or both) dorsal hand \& extensor forearm and desire treatment for this condition that is associated with aging. * women who have had hysterectomies, tubal ligations or who are post-menopausal for at least one year prior to the study may be enrolled. women of childbearing potential who are not pregnant, not planning to become pregnant during the study period, and not lactating may be enrolled if they are using a medically accepted contraceptive program initiated at least one month prior to study entry and continued during the study. * subject is willing to comply with study instructions and return to the clinic for required visits. * subject is able to understand and has signed an irb approved informed consent form including consent for photography. exclusion criteria: * all subjects on coumadin, heparin, plavix, supplemental herbs, vitamin e, empirin, fiorinal, norgesic, forte, percodan, robaxin, nuprin, ansaid, anaprox, clinoril, dolobid, feldene, naprosyn, voltaren, fish oil, oral steroids, or daily use of aspirin, motrin, or advil. (prn usage not excluded) * prior treatment with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids within 3 months of study enrollment is prohibited. * clotting abnormalities as determined by screening labs * any history of a stroke or unstable heart disease * participation in another clinical trial with exposure to any investigational agent within 30 days prior to screening visit. * any condition the investigator believes would interfere with subject's ability to provide informed consent, comply with study instruction, or which might confound the interpretation of the study results or put the subject at undue risk. * subject is pregnant, breastfeeding or planning a pregnancy during the study. * subject is unable to communicate or cooperate with the investigator due to a language barrier (non-english speaking). * subjects who are allergic to adapalene or the ingredients in the gel.

Keywords: senile purpura adapalene 0.3%
the effect of mindfulness intervention program on adolescents' internet addiction

Conditions: Mindfulness; Internet Addiction Disorder; Adolescent Behavior

Summary: the internet shows its presence in areas where human beings are actively involved, from education to health, from entertainment to the investment sector. the integration of the internet into many areas of human life leads to its intensive use. according to the global digital report, the number of individuals with access to the internet worldwide at the beginning of 2024 is stated as 5.35 billion, and this number constitutes more than 66% of the total world population. one of the pioneering studies on internet addiction was conducted by young. in this study, five subtypes of internet addiction were identified. these are cyber sex addiction (obsessive use of adult sites such as cyber sex, cyber porn), cyber relationship addiction (excessive involvement in online relationships), net compulsions (online gambling, shopping and trading), information overload (on websites). and constantly surfing databases) and computer addiction (playing computer games). considering the sub-dimensions of internet addiction, it is seen that it affects many areas of life, from family life to interpersonal relationships, from social life to economic life. conscious awareness is the awareness of one's internal state and environment. mindfulness can help people avoid destructive or automatic habits and reactions by learning to observe their thoughts, feelings, and other momentary experiences without judging or reacting. acting based on awareness is a much different way of life than the autopilot approach in which the individual carries out his daily routines and activities. in studies, mindfulness is examined not only to prevent the recurrence of addiction, but also as a long-term, ongoing health behavior that supports the recovery of addiction. determining the effect of a mindfulness-based intervention program applied to adolescent nursing students studying at a university on internet addiction and awareness. is intended.


Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * being in the adolescent age group (17-19 years old) * studying in turkish nursing department exclusion criteria: • previous participation in a mindfulness intervention program for internet addiction

Keywords: mindfulness internet addiction disorder adolescent behavior
effect of dexmedetomidine on prevention of postoperative nausea and vomiting in children

Conditions: Postoperative Nausea and Vomiting; Post Operative Pain; Emergence Delirium

Summary: this study will aim to evaluate the effects of dexmedetomidine, dexamethasone and ondansetron on the prevention of postoperative nausea and vomiting in children undergoing dental rehabilitation surgery.

postoperative nausea and vomiting (ponv) is one of the most common and unpleasant postoperative complications, which is a major concern in surgical patients. ponv affects about 20-40% of surgical patients, with certain high-risk patients experiencing rates of up to 80%. it has a high incidence in children, especially for tonsillectomy and dental surgery. ponv could lead to several adverse consequences, including dehydration, electrolyte imbalance, and wound dehiscence. it has also been reported ponv is associated with delayed hospital discharge, unplanned hospital admission, and increased financial costs required for patient care. several anti-emetic drugs have been described for the prophylactic control of ponv. dexamethasone is common practice in surgery, as part of a multimodal pain and antiemetic strategy. ondansetron is a selective 5-ht3 receptor antagonist that exhibits an anti-emetic action by antagonizing vomiting signals in the afferent pathway from the stomach or small intestine and solitary tract nucleus and is effective at preventing ponv, however, the high cost of this drug has prevented it from being widely used. dexmedetomidine is a highly selective α2-adrenoreceptor agonist which has been widely used in clinical practice and has been explored extensively in the pediatric population due to its beneficial effects on perioperative morbidities. in the past few years, many studies in paediatrics have been published showing that dexmedetomidine lowered postoperative pain scores and opioid consumption, decreased the incidence of emergence agitation (ea), and improved the quality of recovery in pediatric patients undergoing different surgical procedures. in addition, a small selection of studies reported that dexmedetomidine could lower the incidence of nausea or vomiting after surgery and during the use of patient-controlled analgesia (pca) in paediatrics. however, the effect of dexmedetomidine on ponv remains poorly understood. in this study, investigators will evaluate the effect of dexmedetomidine on preventing postoperative nausea and vomiting in children in comparison with dexamethasone and ondansetron

Eligibility criteria:
inclusion criteria: * pediatric patients 6-12 years. * pediatric patients (asa physical status i, ii). * scheduled for dental rehabilitation surgery exclusion criteria: * parental refusal * allergy or contraindication to studied medication or anaesthetic agents. * children with known gastroesophageal reflux disease. * intake of antiemetic medication within 24 hours before surgery. * past history or family history of previous postoperative nausea and vomiting.

Keywords: dexmedetomidine nausea and vomiting
comparison of the effectiveness of brexpiprazole with that of risperidone

Conditions: Schizophrenia

Summary: to demonstrate that the effectiveness of brexpiprazole (2-4 mg/day) on quality of life is non-inferior to that of risperidone (4-6 mg/day) in adult patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * the patient has schizophrenia diagnosed according to dsm-5™ * the patient has his or her first formal diagnosis of schizophrenia less than 10 years ago * the patient has been prescribed outpatient oral antipsychotic treatment at recommended dose range as stated in the summary of product characteristics or equivalent document/label for the full 3 months prior to the screening visit. * the patient has cgi-s score of 3 (mildly ill) or 4 (moderately ill) at the screening and baseline visits. * the patient has a global assessment scale (gas) score of 41 to 70 (limits included) at the screening and baseline visits. * the patient is in need of a change in the current antipsychotic treatment due to insufficient functional improvement and, in the judgement of the investigator, would benefit from a switch to another treatment. reasons for switching include but are not limited to the following reasons: 1. lack of adequate response to his or her current antipsychotic medication, 2. poor tolerability to his or her current antipsychotic medication, 3. unwillingness of the patient to adhere to his or her current antipsychotic medication. exclusion criteria: * the patient has a psychiatric disorder (dsm-5™ criteria) other than schizophrenia established as the primary diagnosis. * the patient is experiencing acute exacerbation of psychotic symptoms at the screening visit, between the screening and baseline visits or at the baseline visit. * the patient is hospitalised for his or her psychotic symptoms at the screening visit, between the screening and baseline visits or at the baseline visit. * the patient is treated with brexpiprazole, risperidone or clozapine at the time of screening visit. * the patient has shown, in the investigator's judgment, significant lack of efficacy to brexpiprazole, risperidone or paliperidone when treated at recommended dose range as stated in their respective summary of product characteristics or equivalent document/ label, in a manner that would preclude benefiting from the study medication if randomised to brexpiprazole or risperidone during the study. * the patient is considered resistant to antipsychotic treatment according to the investigator's judgement. * the patient is at significant risk of harming himself/herself, or others according to the investigator's judgement or based on the columbia suicide severity rating scale (c-ssrs).
scalp nerve block and opioid consumption in brain surgery

Conditions: Brain Tumour

Summary: anterior scalp block with 0.5% plain marcaine 20 ml. may reduce the intraoperative opioid consumption in neurosurgical patients who undergoing the supratentorial craniotomy compared to those who receive 0.9% normal saline solution (placebo).

anterior scalp block with 0.5% plain marcaine 20 ml. may reduce the intraoperative opioid consumption in neurosurgical patients who undergoing the supratentorial craniotomy compared to those who receive 0.9% normal saline solution (placebo). a prospective randomized double blind control

Eligibility criteria:
inclusion criteria: 1. patients who have supratentorial brain tumor 2. patients have been scheduled to undergo an elective craniotomy to remove tumor in any surgical position 3. patients have been general anesthetized with endotracheal intubation and control ventilation 4. patients who have provided consent for the participation in the research and for the use of their medical record in research exclusion criteria: 1. pregnant patients 2. patients who have a history of local anesthetic allergy and/ or anaphylaxis

Keywords: supratentorial brain tumour craniotomy
effect of moderate weight loss in metabolically abnormal lean subjects

Conditions: Weight Loss

Summary: obesity is associated with a constellation of cardiometabolic abnormalities (including insulin resistance, elevated blood pressure and dyslipidemia) that are risk factors for diabetes and cardiovascular disease. weight loss can improve all of the cardiometabolic abnormalities associated with obesity. up to \~25% of lean people (body mass index \[bmi\] 18.5-24.9 kg/m²) have many of the cardiometabolic abnormalities associated with obesity and are referred to as metabolically abnormal lean (mal) people. however, the mal phenotype is not well characterized, and it is unclear whether weight loss has beneficial metabolic effects in already lean people. accordingly, the goal of this study is to: 1) carefully phenotype mal people and 2) evaluate the effect of moderate (8-10%) diet-induced weight loss in mal people. this will be investigated in 15 mal (defined as having 2 or more of the following: intrahepatic triglyceride (ihtg) content ≥5.6%, glycated hemoglobin ≥5.7%, fasting plasma glucose concentration ≥100 mg/dl, 2-hr oral glucose tolerance test (ogtt) plasma glucose concentration ≥140 mg/dl, homeostatic model assessment of insulin resistance (homa-ir) ≥ 2.5) men and women. only lean people who have a bmi ≥21.0 but \<25.0 kg/m² will be asked to lose weight to avoid the risk that participants become underweight (bmi \<18.5 kg/m²) during weight loss therapy.


Eligibility criteria:
inclusion criteria: * bmi 21.0-24.9 kg/m² * weight stable (+/- 2% for at least 3 months before enrollment) * two or more of the following: ihtg content ≥5.6%, homa- ir index ≥ 2.5, hba1c ≥ 5.7%, 2-hr ogtt plasma glucose concentration ≥ 140 mg/dl, fasting plasma glucose concentration ≥ 100 mg/dl. exclusion criteria: * women who are pregnant or breastfeeding * evidence of significant organ system dysfunction or disease (e.g., diabetes, chronic kidney disease, advanced heart disease, etc.) * men who consume \>21 units (e.g., glass of wine or bottle of beer) of alcohol per week and women who consume \>14 units of alcohol per week * use of dietary supplements or medications known to affect metabolism * eating disorder (assessed by using the eating disorder examination questionnaire \[ede-q\]) * participation in structured endurance or resistance exercise program \>150 min/week * use of tobacco products * unable or unwilling to follow the study protocol or the research team believes that for any reason the volunteer is not an appropriate candidate for this study, including non-compliance with screening appointments or previous appointments/contact arrangements * individuals that take coumadin or similar anticoagulants * use of antibiotics in last 60 days * previous bariatric surgery * cancer or cancer that has been in remission for \<5 years * major psychiatric illness
a study evaluating treatment intensification with abi-h0731 in participants with chronic hepatitis b infection on nucleos(t)ide reverse transcriptase inhibitors

Conditions: Chronic Hepatitis B

Summary: this study will explore the safety and antiviral activity of abi-h0731 when added to a nucleos(t)ide reverse transcriptase inhibitor (nrti) in participants who are partially virologically suppressed.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) 18 to 36 kg/m\^2 and a minimum body weight of 45 kg (inclusive) * in good general health except for chronic hepatitis b (chb) * hbeag positive or hbeag negative chronic hepatitis b * hbv dna \>lloq using a commercially available assay with lloq=20 iu/ml * on a stable nrti regimen (etv, tdf or taf) for more than 12 months * lack of cirrhosis or advanced liver disease exclusion criteria: * current or prior treatment for chb with lamivudine, telbivudine, adefovir, hbv core inhibitor, or previous treatment with an investigational agent for hbv infection * presence of substitutions in the hbv polymerase coding region which may confer reduced susceptibility to nrtis * co-infection with human immunodeficiency virus, hepatitis a virus, hepatitis c virus, hepatitis e virus, or hepatitis d virus * females who are lactating or wish to become pregnant during the course of the trial * history or evidence of advanced liver disease or hepatic decompensation * clinically significant cardiac disease including poorly-controlled or unstable hypertension; pulmonary disease; chronic or recurrent renal or urinary tract disease; liver disease other than chb; endocrine disorder; autoimmune disorder; poorly controlled diabetes mellitus; neuromuscular, musculoskeletal, or mucocutaneous conditions requiring frequent treatment, seizure disorders requiring treatment; ongoing infection or other medical conditions requiring frequent medical management or pharmacologic or surgical treatment that, in the opinion of the investigator or the sponsor, makes the subject unsuitable for trial participation * history of hepatocellular carcinoma (hcc) * exclusionary laboratory parameters at screening: * platelet count \<100,000/mm\^3 * albumin \<lower limit of normal * total bilirubin \>1.2 × upper limit of normal (uln) * direct bilirubin \>1.2 × uln * alt \>10 × uln * serum alpha fetoprotein (afp) ≥100 ng/ml. if afp at screening is \>uln but \<100 ng/ml, the participant is eligible if a hepatic imaging trial prior to initiation of study drug reveals no lesions indicative of possible hcc. * international normalized ratio \>1.5 × uln * glomerular filtration rate \<50 ml/min/1.73 m\^2 by chronic kidney disease epidemiology collaboration equation * any other laboratory abnormality deemed clinically significant by the sponsor or the investigator.
evaluation of the active living every day exercise program for people with arthritis

Conditions: Arthritis

Summary: the primary goal of this study is to assess the effectiveness and feasibility of the active living every day physical activity program (aled) for people with arthritis. this project is designed to evaluate the effectiveness of the aled program in changing arthritis-related health outcomes and to investigate the feasibility of conducting the aled program in a public health setting.

evidence has shown that regular moderate-intensity physical activity improves symptoms and function in persons with arthritis. a 20-week behavior-based program was developed by the cooper institute, brown university, and human kinetics to help people with sedentary lifestyles become and stay physically active. a randomized trial evaluated the effectiveness and efficacy of a similar program on which active living every day is based (aled) on cardiovascular disease risk factors, cost-effectiveness, and cardiorespiratory fitness. however, the current research supporting aled is limited for people with arthritis. the primary goal of this study is to assess the effectiveness and feasibility of the active living every day physical activity program (aled) for people with arthritis. the primary goal will be accomplished through a twenty week randomized controlled trial conducted with 400 participants residing in the 17 area agencies on aging housed in the councils of government in north carolina, including both urban and rural counties. this project is designed to evaluate the effectiveness of the aled program in changing arthritis-related health outcomes and to investigate the feasibility of conducting the aled program in a public health setting. objectives: 1. to demonstrate that the aled program can increase physical activity and fitness levels among people with arthritis. 2. to demonstrate that the active living every day has arthritis-specific benefits. 3. to evaluate the feasibility of disseminating the active living every day program through the nc public health network.

Eligibility criteria:
inclusion criteria: * self-reported arthritis or chronic joint symptoms * currently exercising less than 3 times per week * plan to be in community for at least 1 year * physician release for participation in physical activity exclusion criteria: * pregnancy * non-english speaking * cognitive impairment * serious medical condition where exercise is contradindicated * severe physical or mental impairment

Keywords: arthritis osteoarthritis rheumatoid arthritis rheumatic disease exercise physical activity physical function disability
mucociliary clearance in healthy subjects: comparison of levalbuterol and racemic albuterol

Conditions: Mucociliary Clearance

Summary: the purpose of this study is to determine whether lung mucociliary clearance (mcc) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. subjects will inhale one week of levalbuterol, one week of racemic albuterol, and one week of placebo, in a randomized order.

in healthy lungs, inhaled insoluble material such as bacteria, viruses, antigens, and toxins deposit in the tracheobronchial airway mucus and are removed from the lung in a matter of hours by mucociliary clearance (mcc). when mcc is overwhelmed or impaired, some mucus can be removed by mechanical or cough clearance (cc). impairment of mcc typically leads to the accumulation of mucus in the airways, and this in turn is associated with acute infections, chronic bacterial colonization, and chronic inflammation. racemic albuterol has been shown to stimulate mcc in various patient populations. inhaled and subcutaneous terbutaline has also been shown to stimulate mcc in healthy subjects. we hypothesize that levalbuterol will be more potent than racemic albuterol in enhancing mcc and cc in healthy subjects.

Eligibility criteria:
inclusion criteria: * non-smoking males and non-pregnant females greater than or equal to 18 years of age * forced expiratory volume in one second (fev1) and forced vital capacity (fvc) greater than or equal to 80% of predicted values * normal systolic and diastolic blood pressures exclusion criteria: * history of heart disease, irregular heartbeat, hypertension * history of diabetes, hyperthyroid * history of pneumonia, tuberculosis * history of seizure disorder, depression, hospitalization in the last month for non-elective purposes, cold or flu in the previous three months

Keywords: mucociliary clearance beta-adrenergic drugs inhalation aerosol